We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026

Intelligent Pill Targets Digestive Tract Diseases

By HospiMedica International staff writers
Posted on 02 Dec 2008
A new intelligent pill technology will assist drug development and enable new therapies for debilitating and life-threatening digestive tract disorders such as Crohn's disease, colitis, and colon cancer. More...


The iPill, called the "next generation” of the camera pill, is delivered in a capsule, the same size as a camera pill, and has been designed to be swallowed and to pass through the digestive track naturally. It can be electronically programmed to control the delivery of medicine according to a pre-defined drug release profile. The iPill determines its location in the intestinal tract by measuring the local acidity of its environment. Armed with this pH information and data about capsule transit times, the location in the gut can be determined with good accuracy. The iPill then releases medicine from its drug reservoir via a microprocessor-controlled pump, allowing accurate programmable drug delivery. In addition, the capsule is designed to measure local temperature, and report measurements wirelessly to an external receiver unit. The iPill is being developed by Royal Philips Electronics (Amsterdam, The Netherlands),

"The combination of navigational feedback, electronically controlled drug delivery and monitoring of the intestinal tract promises to make iPill technology a valuable research tool for drug development,” said pharmaceutical drug delivery expert Karsten Cremer, Ph.D., of Pharma Concepts (Basel, Switzerland). "In particular, I recognize the potential of this technology to improve drug candidate profiling and selection, which could ultimately accelerate the development of new drugs.”
"As part of Philips' commitment to provide integrated solutions for patient care, we are exploring the potential benefits of our technologies in the therapeutic arena,” said Henk van Houten, senior vice president of Philips Research and head of the healthcare research program. "We foresee that technologies like the iPill, that combine electronics with diagnostic and therapeutic properties, will open up the possibility of targeting almost any kind of drug to a specific location in the intestinal tract.”

Distinct areas of the intestinal tract have distinct pH profiles; the stomach is highly acidic, upon exiting the stomach the acidity of the gut sharply decreases, and then becomes progressively less acidic from the upper intestine onwards to the lower intestine.

Related Links:
Royal Philips Electronics
Pharma Concepts


Gold Member
12-Channel ECG
CM1200B
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Hybrid Arch Device
Neo EDE
New
Monitor/Defibrillator
Zenix
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.